Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2018 at "PharmacoEconomics"
DOI: 10.1007/s40273-018-0625-6
Abstract: BackgroundThe recently completed ALEX trial demonstrated that alectinib improved progression-free survival, and delayed time to central nervous system progression compared with crizotinib in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer. However, the long-term clinical… read more here.
Keywords: alectinib crizotinib; anaplastic lymphoma; cost; alectinib ... See more keywords
Sequential Therapy with Crizotinib and Alectinib in ALK‐Rearranged Non–Small Cell Lung Cancer—A Multicenter Retrospective Study
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2016.07.022
Abstract: Introduction: Alectinib and crizotinib have been approved for the therapy of NSCLC caused by anaplastic lymphoma kinase gene (ALK) rearrangement. The effect of alectinib or crizotinib on overall survival (OS) in patients with ALK‐rearranged NSCLC… read more here.
Keywords: alectinib crizotinib; crizotinib; treated group; crizotinib alectinib ... See more keywords